| abstract |
The present invention provides a compound for use in the prophylaxis and/or treatment of amyotrophic lateral sclerosis (ALS), wherein said compound is selected from the group consisting of bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib and bafetinib. Particularly, using a compound already on the market as a pharmaceutical product, a pharmaceutical product for the prophylaxis or treatment of ALS can be developed rapidly at a low cost. |